External validation of a serum tumor marker algorithm for early prediction of no durable benefit to immunotherapy in metastastic non-small cell lung carcinoma

External validation of a serum tumor marker algorithm for early prediction of no durable benefit to immunotherapy in metastastic non-small cell lung carcinoma

Background Immune checkpoint inhibitors (ICIs) provide a significant survival benefit in non-small cell lung cancer (NSCLC) patients; however, accurately predicting which patients will benefit remains a challenge. As previously shown, the STOP model, a machine learning model based on serum tumor mar...

Full description

Saved in:
Bibliographic Details
Main Authors: Milou M. F. Schuurbiers, Freek A. van Delft, Hendrik Koffijberg, Maarten J. IJzerman, Kim Monkhorst, Marjolijn J. L. Ligtenberg, Daan van den Broek, Huub H. van Rossum, Michel M. van den Heuvel
Format: Article
Language:English
Published: SAGE Publishing 2025-02-01
Series:Tumor Biology
Online Access:https://doi.org/10.1177/14230380251316788
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://doi.org/10.1177/14230380251316788

Similar Items